Why did ABOS miss its Q4 2023 earnings forecast completely?

Acumen Pharmaceuticals, Inc. (ABOS) did not miss its Q4 2023 earnings forecast completely. The company's financial results for the year ended December 31, 2023, were reported with a net loss of $52.4 million. However, when comparing the Q4 2023 earnings, the company reported a net loss of $102.3 million for the year, which includes the Q4 results. The increase in net loss was primarily due to increased research and development expenses, totaling $93.8 million in 2024, primarily due to the ALTITUDE-AD clinical trial.